Tenax Therapeutics Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chris Giordano

Algemeen directeur

US$644.8k

Totale compensatie

Percentage CEO-salaris	62.9%
Dienstverband CEO	3.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20

Analyse CEO-vergoeding

Hoe is Chris Giordano's beloning veranderd ten opzichte van Tenax Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$645k	US$405k	-US$8m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$667k	US$386k	-US$11m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$861k	US$183k	-US$32m

Compensatie versus markt: De totale vergoeding ($USD 644.77K ) Chris } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 654.40K ).

Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chris Giordano (50 yo)

3.3yrs

Tenure

US$644,770

Compensatie

Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Giordano	CEO, President & Director	3.3yrs	US$644.77k	geen gegevens
Stuart Rich	Chief Medical Officer & Director	3.8yrs	US$481.22k	0.043% $ 6.5k
Lawrence Hoffman	Interim Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Doug Randall	Executive Vice President of Commercial & Business Operations	no data	geen gegevens	geen gegevens
Douglas Hay	Senior Vice President of Regulatory Affairs	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TENX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Giordano	CEO, President & Director	3.3yrs	US$644.77k	geen gegevens
Stuart Rich	Chief Medical Officer & Director	3.8yrs	US$481.22k	0.043% $ 6.5k
Gerald Proehl	Independent Chairman	10.6yrs	US$88.50k	0.049% $ 7.5k
Michael Davidson	Independent Director	3.8yrs	US$57.50k	0.085% $ 12.9k
Daniel Burkhoff	Member of PH-Left Heart Disease Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Declan Doogan	Independent Director	3.8yrs	US$48.50k	0.067% $ 10.2k
Robyn Hunter	Independent Director	2.8yrs	US$65.00k	0% $ 0
June Almenoff	Independent Director	3.8yrs	US$59.50k	0% $ 0
Sanjiv Shah	Member of PH-Left Heart Disease Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Barry Borlaug	Member of PH-Left Heart Disease Scientific Advisory Board	4.8yrs	geen gegevens	geen gegevens
Robert Frantz	Member of PAH Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anna Hemnes	Member of PAH Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TENX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Tenax Therapeutics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces Resignation of Executives

High number of new and inexperienced directors

Recent updates

New minor risk - Profitability

Tenax Therapeutics, Inc. announced that it has received $99.681169 million in funding from a group of investors

Tenax Therapeutics, Inc. announced that it expects to receive $99.681169 million in funding from a group of investors

New minor risk - Share price stability

Tenax Therapeutics, Inc. announced that it expects to receive $99.999996 million in funding from a group of investors

New major risk - Revenue and earnings growth

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Profitability

Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics Receives Non-Compliance Notice from Nasdaq

Forecast to breakeven in 2026

Tenax Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Tenax Therapeutics's Request for an Extension Through March 25, 2024 to Evidence Compliance with the $1.00 Per Share Requirement for Continued Inclusion on the Nasdaq Capital Market

Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application

Price target increased by 16% to US$110

Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Tenax Therapeutics, Inc. Receives Formal Notice That the Nasdaq Stock Market LLC

Forecast to breakeven in 2023

Tenax Therapeutics, Inc. Announces Resignation of Executives

Price target decreased to US$4.00

Tenax Therapeutics, Inc. Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc. announced that it expects to receive $8 million in funding from Armistice Capital LLC

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

High number of new and inexperienced directors

Forecast to breakeven in 2022

Price target increased to US$4.75

Independent Director James Mitchum has left the company

Tenax Therapeutics, Inc. Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

High number of new directors

CEO & Director Anthony DiTonno has left the company

Independent Director Chris Rallis has left the company

Independent Director Gregory Pepin has left the company

Independent Chairman Ronald Blanck has left the company

Price target increased to US$4.75

Tenax Therapeutics, Inc. Expands Board of Directors

New 90-day high: US$2.78

Tenax Therapeutics, Inc. (NasdaqCM:TENX) acquired PH Precision Med Inc. for $21.6 million.

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

New 90-day high: US$2.36

New 90-day high: US$1.98

Tenax Therapeutics, Inc. Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

New 90-day low: US$1.18

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

New 90-day high: US$1.63

Price target lowered to US$4.23

Tenax Therapeutics, Inc. announced that it has received $4.735325 million in funding

Tenax Therapeutics, Inc. announced that it expects to receive $4.735325 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd